Skip to playerSkip to main content
  • 11 years ago
At a time when many large pharma companies are slashing costs and cutting deals, blood plasma therapeutics specialist CSL Limited is increasing R&D spending to build value, says the company's CEO Paul Perreault. Perreault says the company's R&D mode
Be the first to comment
Add your comment

Recommended